{'fraction_non_alphanumeric': 0.029925187032418952, 'fraction_numerical': 0.004987531172069825, 'mean_word_length': 5.176923076923077, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Tamoxifen reduced breast cancer risk but increased risks of thromboembolic events and all cause mortality in women

Main results Analysis was by intention to treat. Tamoxifen reduced the risk of breast cancer more than did placebo (table); age ( < 50 or ≥ 50 y), hormone replacement therapy use (during or before the trial, or never), and definition of invasiveness (ductal carcinoma in situ or invasive disease) did not affect this reduction. Tamoxifen increased the rates of thromboembolic events and all cause mortality (table), but no difference existed for rates of endometrial cancer or cardiovascular events (table). Conclusion In women with an increased risk of breast cancer, tamoxifen reduced the risk of breast cancer but increased the risks of thromboembolic events and all cause mortality.